These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17250731)

  • 41. [Spasticity and botulinum toxin in 2003. An update].
    Fève A
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):265-70. PubMed ID: 12746701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury.
    Verplancke D; Snape S; Salisbury CF; Jones PW; Ward AB
    Clin Rehabil; 2005 Mar; 19(2):117-25. PubMed ID: 15759526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with botulinum toxin type B for upper-limb spasticity.
    Brashear A; McAfee AL; Kuhn ER; Ambrosius WT
    Arch Phys Med Rehabil; 2003 Jan; 84(1):103-7. PubMed ID: 12589629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Balance dysfunction in hereditary and spontaneous spastic paraparesis.
    Marsden J; Stevenson V
    Gait Posture; 2013 Sep; 38(4):1048-50. PubMed ID: 23587557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin injection of spastic finger flexors in hemiplegic patients.
    Rodriquez AA; McGinn M; Chappell R
    Am J Phys Med Rehabil; 2000; 79(1):44-7. PubMed ID: 10678602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin.
    Clark GT
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):727-48. PubMed ID: 14580034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Experiences with botulinum toxin injections against spasticity in children].
    Ramstad K; Karstensen AB; Risberg K; Bergsaker DK; Sommer FF
    Tidsskr Nor Laegeforen; 2006 Feb; 126(4):450-2. PubMed ID: 16477283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment of spastic paraparesis with botulinum toxin with reference to beneficial effects, disease severity and long-term treatment].
    Takenaga S; Kawahigashi Y; Sonoda Y; Horikiri T; Hirata K; Arimura K; Osame M
    Rinsho Shinkeigaku; 1995 Mar; 35(3):251-5. PubMed ID: 7614746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computerized gait analysis of botulinum toxin treatment in children with cerebral palsy.
    Galli M; Cimolin V; Valente EM; Crivellini M; Ialongo T; Albertini G
    Disabil Rehabil; 2007 Apr; 29(8):659-64. PubMed ID: 17453987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pilocarpine for the treatment of refractory dry mouth (xerostomia) associated with botulinum toxin type B.
    Dave SJ
    Am J Phys Med Rehabil; 2008 Aug; 87(8):684-6. PubMed ID: 18645325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nerve stimulation boosts botulinum toxin action in spasticity.
    Frasson E; Priori A; Ruzzante B; Didonè G; Bertolasi L
    Mov Disord; 2005 May; 20(5):624-9. PubMed ID: 15726575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of botulinum toxin injections on gait control in spastic stroke patients presenting with a stiff-knee gait.
    Bleyenheuft C; Cockx S; Caty G; Stoquart G; Lejeune T; Detrembleur C
    Gait Posture; 2009 Aug; 30(2):168-72. PubMed ID: 19442523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Botulinum toxin A in the treatment of hemiplegic spastic foot drop--clinical and functional outcomes.
    Chua KS; Kong KH; Lui YC
    Singapore Med J; 2000 May; 41(5):209-13. PubMed ID: 11063169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin injections for pediatric patients with hereditary spastic paraparesis.
    Geva-Dayan K; Domenievitz D; Zahalka R; Fattal-Valevski A
    J Child Neurol; 2010 Aug; 25(8):969-75. PubMed ID: 20406997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are gait and mobility measures responsive to change following botulinum toxin injections in adults with lower limb spasticity?
    Chan J; Winter A; Palit M; Sturt R; Graaff Sd; Holland AE
    Disabil Rehabil; 2013 Jun; 35(12):959-67. PubMed ID: 23025332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot.
    Cioni M; Esquenazi A; Hirai B
    Am J Phys Med Rehabil; 2006 Jul; 85(7):600-6. PubMed ID: 16788391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of hip adductor spasticity with botulinum toxin type B].
    Oechsner M
    Nervenarzt; 2002 Dec; 73(12):1179-82. PubMed ID: 12486568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications.
    Miscio G; Del Conte C; Pianca D; Colombo R; Panizza M; Schieppati M; Pisano F
    J Neurol; 2004 Feb; 251(2):189-96. PubMed ID: 14991354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Local botulinum toxin in the treatment of spastic drop foot.
    Dengler R; Neyer U; Wohlfarth K; Bettig U; Janzik HH
    J Neurol; 1992 Aug; 239(7):375-8. PubMed ID: 1403018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Botulinum toxin type A versus phenol. A clinical and neurophysiological study in the treatment of ankle clonus.
    Manca M; Merlo A; Ferraresi G; Cavazza S; Marchi P
    Eur J Phys Rehabil Med; 2010 Mar; 46(1):11-8. PubMed ID: 20332721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.